A randomized phase II study of intermittent chemotherapy or intermittent chemotherapy with maintenance GM-CSF [sargramostim] in patients with previously untreated hormone-refractory prostate cancer

Trial Profile

A randomized phase II study of intermittent chemotherapy or intermittent chemotherapy with maintenance GM-CSF [sargramostim] in patients with previously untreated hormone-refractory prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs Sargramostim (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jan 2015 Status changed from active, no longer recruiting to completed.
    • 09 Apr 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top